Latest News
-
Thursday - August 16, 2018
Following completion of the divestment of Crop Science businesses to BASF
Bayer: Conditions for beginning Monsanto integration fulfilled
Legal remedies against jury verdict in California announced » more
-
Tuesday - August 14, 2018
Not intended for U.S. and UK Media - Specialty lung disease
Bayer and Haplogen collaborate to develop new treatments against pulmonary diseases » more
-
Friday - August 10, 2018
Not intended for U.S. and UK Media - New rivaroxaban data to be presented at ESC Congress 2018:
Bayer announces acceptance of nine abstracts on the use of Xarelto® in patients from a broad range of clinical and real-world studies
New COMPASS data about bleeding and cancer risk in patients with vascular disease / Late-breaking abstracts feature results from the COMMANDER HF study, which investigated the use of Xarelto in patients following an acute episode of worsening heart failure and concomitant coronary artery disease, and the MARINER study that investigated high-risk medically ill patients / Further Xarelto abstracts accepted for presentation include both clinical and real-world studies in venous and arterial thromboembolism » more
-
Friday - August 10, 2018
Platinum Sponsor at the 30th International Horticultural Congress in Istanbul:
Bayer showcases Root2Success for healthy soils and roots » more
-
Friday - August 3, 2018
Grant4Impact – Bayer’s new energizer program:
Bayer Cares Foundation promotes sustainable growth by supporting social impact pioneers with grants totaling EUR 1 million
Two years’ support for five social impact start-ups in healthcare and nutrition / Visionary entrepreneurs helping to improve millions of people’s lives / Grant for handheld breast cancer screening device developed in the USA and being piloted in Brazil » more
-
Wednesday - August 1, 2018
Not intended for U.S. and UK Media
Bayer receives approval of new treatment regimen for Eylea® in the EU
New treatment regimen could offer patients with neovascular age-related macular degeneration (AMD) extended proactive dosing already in the first year, while delivering strong visual gains / Data from ALTAIR study demonstrate sustainability of new approach in 57% of patients who extended their treatment interval to 12 weeks or more » more
-
Tuesday - July 31, 2018
LEO Pharma to expand its lead in medical dermatology with acquisition of Bayer’s prescription dermatology unit
Significant step to bolster LEO Pharma’s role as a leading global dermatology company with its goal of helping 125 million patients by 2025 » more
-
Friday - July 27, 2018
Not intended for U.S. and UK Media
Bayer receives positive CHMP opinion for rivaroxaban for patients with coronary or peripheral artery disease
Positive CHMP opinion based on data from the largest Phase III rivaroxaban study, COMPASS / Once approved, rivaroxaban will be the only non-vitamin K antagonist oral anticoagulant (NOAC) indicated in combination with acetylsalicylic acid (ASA) for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk for ischaemic events » more
-
Friday - July 27, 2018
Bayer to appeal against recent General Court verdict on neonicotinoids » more
-
Tuesday - July 24, 2018
Not intended for U.S. and UK Media
Bayer receives approval for Kovaltry® in China for the treatment of children and adults with Hemophilia A » more
-
Monday - July 23, 2018
Bayer Foundation awards 26 scholarships for Science Camp during summer vacation:
Young scientists experimenting on health and food science topics at Bayer Science Teens Camp in the U.S.
International exchange: Pupils from Germany, India, Africa and the U.S. taking part in two-week, hands-on seminar focusing on life science, medical health and food science topics / Bayer partnering with renowned Center for STEM Learning at University of Colorado in Boulder » more
-
Thursday - July 12, 2018
Bayer continues commitment to improving feline medicine and health with symposium at ISFM congress
Bayer recently supported the International Society of Feline Medicine (ISFM) 2018 European Congress, with platinum sponsorship of the event / A symposium organised by Bayer at the Congress, saw leading experts discuss the latest information on two feline infectious diseases / Key messages included how to minimise the risk of a mycoplasmal infection and the threat of feline leishmaniosis » more
-
Monday - July 9, 2018
Not intended for U.S. and UK Media - Data published in Journal of the American College of Cardiology
XANTUS programme confirms low bleeding and low stroke rate with Xarelto® in 11,121 prospectively investigated patients with atrial fibrillation
Outcomes from real-world patients with atrial fibrillation (AF) confirm low bleeding and low stroke rates for Xarelto / Conclusions from pooled analysis of the three non-interventional studies, spanning three regions and 47 countries » more
-
Wednesday - July 4, 2018
Search for novel parasite prevention:
Bayer Animal Health and Mitsui Chemicals Agro sign global license agreement
Bayer to expand its strong parasiticide portfolio for companion animals with new compounds derived from MCAG’s chemical library / License agreement is the result of the long-term collaboration between Bayer and MCAG » more
-
Monday - July 2, 2018
Seresto® now offers protection with new licensing in many European countries to reduce the risk of canine leishmaniosis
Seresto is now licensed to reduce the risk of infection with Leishmania infantum in dogs via transmission by sandflies for up to eight months in many European countries / Canine leishmaniosis is a vector-borne disease with global significance / L. infantum is zoonotic, potentially causing severe disease in dogs, as well as humans » more
-
Friday - June 29, 2018
Not intended for U.S. and UK Media - Precision cardiovascular research
Bayer expands strategic alliance with Broad Institute of MIT and Harvard
Joint Precision Cardiology Laboratory will focus on using innovative technologies to better understand cardiovascular diseases on a molecular level and to pursue new drug targets / Additional investment of up to $22 million over 5 years » more
-
Thursday - June 21, 2018
Bayer demonstrates its commitment to human rights
Bayer supports a new UN code opposing discrimination against lesbian, gay, bisexual, transgender and intersex (LGBTI) people » more
-
Tuesday - June 19, 2018
Bayer concludes refinancing of the Monsanto acquisition by placing bonds with a volume of 5 billion euros
Issue of four tranches with maturities of 4 to 11½ years was more than four times oversubscribed » more
-
Tuesday - June 19, 2018
Bayer issues new bonds with a volume of 15 billion U.S. dollars
Successful international placement secures long-term financing of the Monsanto acquisition / Issue of eight tranches with maturities of three to 30 years was approximately three times oversubscribed » more
-
Monday - June 11, 2018
25th International Pig Veterinary Society Congress:
Bayer drives scientific exchange and digital tools to advance swine well-being and health
Global experts at 7th International Bayer Pig Symposium address topics key to swine production: piglet and sow management, biosecurity and responsible use of antibiotics / Bayer launches BCS SowDition and Power Pigs, smartphone apps. to help swine professionals analyse and track body condition scores of sows, as well as learn more about pig health and well-being solutions in an augmented reality-based game » more
Copyright @ Bayer AG
Search
Publications
Newsletter
Events
Saturday, August 25, 2018
European Society of Cardiology (ESC), August 25-29, 2018, Munich, Germany
Additional Press Events
Investor Relations Events
BayKomm Events
Download Center - Selection
Bayer TV